The University of Hawaii established its cancer center in 1981 on the island of Oahu in Hawaii’s capital city, Honolulu. It received its National Cancer Institute designation in 1996. This designation recognizes the center as one of the best cancer research institutions in the world and requires it to meet stringent requirements and undergo constant evaluation.

The University of Hawaii Cancer Center focuses strongly on cancer research in an effort to find better treatment techniques and diagnostic tools. As of 2018, this cancer is one of a mere 70 research institutes to receive designation from the National Cancer Institute. Researchers at the University of Hawaii Cancer Center work in three interdisciplinary programs: epidemiology (a science that deals with the distribution and control of diseases), cancer biology and cancer prevention and control. Within those programs, they conduct cutting-edge research in areas like epidemiology, molecular carcinogenesis, cancer treatment and prevention methodology. An important aspect of the cancer center’s work is outreach to Hawaii’s multiethnic community, including education, particularly about prevention, and support programs for cancer survivors.

The University of Hawaii Cancer Center is a global leader in mesothelioma research. Under the leadership of center director Michele Carbone, a pathologist who specializes in mesothelioma, researchers at the center have made important discoveries about the disease. They have identified the gene that causes mesothelioma, BAP1, and a protein that is critical in the development of the disease, which has led to many studies internationally to better understand the connection.

The University of Hawaii Cancer Center continues their research through clinical trials. Clinical trials allow eligible mesothelioma patients to try emerging treatments that have not yet become available to everyone. The cancer center acknowledges that cancers like malignant mesothelioma can be very aggressive, and standard treatment options may not be the best option for all patients.


  • Cancer research
  • Clinical trials


  • National Cancer Institute Designated Cancer Center
  • National Cancer Institute Community Oncology Research Program designation

Mesothelioma Clinical Trials at University of Hawaii Cancer Center

The following clinical trials are in progress or actively recruiting participants at University of Hawaii Cancer Center:

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Conditions: Carcinoma, Carcinoma, Squamous Cell, Adenocarcinoma, Neoplasms, Germ Cell and Embryonal, Mesothelioma, Breast Neoplasms, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Carcinoma, Basal Cell, Gastrointestinal Stromal Tumors, Carcinoid Tumor, Carcinoma, Transitional Cell, Carcinoma, Adenoid Cystic, Teratoma, Adenocarcinoma of Lung, Carcinoma, Neuroendocrine, Seminoma, Pheochromocytoma, Choriocarcinoma, Cystadenocarcinoma, Cystadenocarcinoma, Serous, Carcinoma, Endometrioid, Chordoma, Paraganglioma, Hemangiosarcoma, Fibromatosis, Aggressive, Trophoblastic Neoplasms, Adenocarcinoma, Mucinous, Gestational Trophoblastic Disease, Adenocarcinoma, Clear Cell, Nerve Sheath Neoplasms, Neurofibrosarcoma, Cystadenocarcinoma, Mucinous, Fibroma, Thyroid Neoplasms, Pseudomyxoma Peritonei, Sex Cord-Gonadal Stromal Tumors, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Vulvar Neoplasms, Paget Disease, Extramammary, Adenocarcinoma, Papillary, Carcinoma, Acinar Cell, Adenocarcinoma, Bronchiolo-Alveolar, Mixed Tumor, Mullerian, Carcinoma, Giant Cell, Neoplasms, Unknown Primary, Neoplasms

Last Updated: September 27, 2019

Status: Recruiting

Photo of University of Hawaii Cancer Center

Get Help Contacting University of Hawaii Cancer Center

    Privacy policy: All information is secure and will never be released



    Mesothelioma Treatment Guide

    Please fill in the form to request our FREE Mesothelioma Treatment Guide.
    It will be sent to you within 24 hours.

    Free Mesothelioma Treatment Guide

      Privacy policy: All information is secure and will never be released